Big Risks in Genzyme As Sanofi-Aventis Bid Goes Hostile (GENZ, SNY)
The Sanofi-Aventis (NYSE: SNY) acquisition attempt of Genzyme Corp. (NASDAQ: GENZ) is taking a turn in a strange direction. The company is holding out for more than the $69.00 cash offer on the table,…